Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade

BACKGROUND: Development of novel agents targeting the androgen axis has led to improved overall survival in castration-resistant prostate cancer (CRPC). This study aimed to investigate the optimal timing of treatment with one such agent, abiraterone acetate (AA), in Japanese patients. MATERIALS AND...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Prostate Int
Main Authors: Nagai, Takashi, Naiki, Taku, Iida, Keitaro, Etani, Toshiki, Ando, Ryosuke, Hamamoto, Shuzo, Sugiyama, Yosuke, Akita, Hidetoshi, Kubota, Hiroki, Hashimoto, Yoshihiro, Kawai, Noriyasu, Yasui, Takahiro
Formato: Artigo
Idioma:Inglês
Publicado em: Asian Pacific Prostate Society 2018
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5857185/
https://ncbi.nlm.nih.gov/pubmed/29556485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.prnil.2017.07.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados